Because exaggerated responses to negatively valenced emotional stimuli in circuits that include these structures are characteristic of several stress-related psychiatric disorders, the ability of SRX246, a novel AVPR1a antagonist, to attenuate the response to angry faces supports the potential of AVPR1a antagonism as a new approach to the treatment of these indications. The gene discussed is AVPR1A; the disease is psychiatric disorder.